Aptar’s Bidose Nasal System Delivers CARDAMYST™ (etripamil), the First and Only Self-Administered FDA-Approved Nasal Spray for Paroxysmal Supraventricular Tach…

Aptar Group, Inc. (NYSE: ATR), a global leader in drug and consumer product dosing, dispensing and protection technologies, ...

Milestone Receives FDA Approval of CARDAMYST™ (etripamil) as First and Only Self-Administered Nasal Spray for Adults with Paroxysmal Supraventricular Tachycardia (…

First FDA approved treatment in 30+ years for more than 2 million Americans with PSVT Novel nasal spray designed to rapidly ...
Healio

FDA approves self-administered nasal spray for paroxysmal supraventricular tachycardia

Milestone Pharmaceuticals announced the FDA approval of prescription etripamil nasal spray for the treatment of acute ...
TCTMD

Etripamil Nasal Spray Gains FDA Approval for Acute Paroxysmal SVT

The self-administered treatment rapidly converts patients into sinus rhythm and may reduce trips to the hospital.
InvestorsHub on MSN

Milestone Pharmaceuticals shares rally after FDA greenlights first at-home PSVT nasal therapy

Milestone Pharmaceuticals (NASDAQ:MIST) shares jumped roughly 35% after the U.S. Food and Drug Administration approved ...

Milestone Wins FDA Approval For First Self-Use Nasal Spray For Sudden Fast Heartbeats

The FDA approved Milestone Pharmaceuticals' Cardamyst nasal spray for acute episodes of PSVT in adults. First treatment for ...
NBC4 Columbus

Milestone Pharmaceuticals to Present New Analysis from Investigational Etripamil Nasal Spray Clinical Trials for PSVT at the American Heart Association Scientific Sessions 2025

Analysis of data from 622 unique enrolled patients across multiple trials showed consistent efficacy of etripamil across multiple study phases, types of trial design, and geographic regions, with ...